top of page
Blue Bees Therapeutics
Blue Bees is developing first-in-class immunotherapies based on a breakthrough technology exploiting dual targeting of cell receptors coupled to heparan sulphate proteoglycans (HSPGs). This innovative approach aims to boost the anti-tumour immune response and open up new therapeutic prospects.
PSCC's entrance
Décembre 2025
Localization
FR - Île-de-France
Modality
Immunotherapy
Development status
Biotech - Pre-IND/Pre-CTA
Lauréat (s)
bottom of page



